Mosaic Neuroscience offers an open research infrastructure that uses AI‑driven analytics to identify biologically distinct subtypes within neurodegenerative diseases such as ALS, Alzheimer’s, Parkinson’s and frontotemporal dementia. The platform provides cloud‑based, standardized drug‑testing environments and a shared data repository, enabling pharma, biotech and academic teams to run subtype‑informed trials, reduce development costs, and improve the chances of disease‑modifying therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Neurodegenerative diseases such as ALS, Alzheimer’s, Parkinson’s, and frontotemporal dementia consist of multiple biological subtypes, yet current research and drug development pipelines treat them as single entities. This mismatch leads to high failure rates in late‑stage trials and prevents therapies from targeting the specific mechanisms driving each patient’s disease.
Solution
Mosaic Neuroscience provides an open research infrastructure that enables subtype‑informed drug development for neurodegenerative disorders. Using AI‑driven analytics, the platform discovers biologically distinct patient subpopulations within heterogeneous disease cohorts. It then offers shared drug‑testing platforms where investigators can evaluate candidate therapies across these defined subtypes, generating more precise efficacy signals. Each experiment feeds back into a continuously expanding dataset, improving the system’s predictive power over time. By making the infrastructure collaborative and reusable, Mosaic reduces development costs and accelerates the identification of disease‑modifying treatments.
Target Audience
Primary customers are pharmaceutical companies, biotech research teams, and academic consortia developing therapies for ALS, Alzheimer’s, Parkinson’s, and frontotemporal dementia.
Features
- AI algorithms for unsupervised subtype discovery across genomic, proteomic, and clinical data
- Standardized, cloud‑based drug testing environments that support multi‑arm trials on defined patient subgroups
- Integrated data repository that aggregates results from all users, enabling continuous learning and model refinement
- Open APIs and interoperability tools for seamless integration with existing research pipelines and biobank resources
- Secure, privacy‑preserving data handling compliant with regulatory standards for patient information